| P2093 | author name string | Jean-Luc Dreyer | |
| P2860 | cites work | The EMBO Journal | Q1278554 |
| | European Journal of Neuroscience | Q5412733 |
| | International Journal of Oncology | Q6051527 |
| | The Journal of Clinical Psychiatry | Q7743563 |
| | Trends in Molecular Medicine | Q15265842 |
| | The prevalence of multiple sclerosis in the world: an update | Q22252675 |
| | Environmental risk factors for multiple sclerosis. Part I: The role of infection | Q22252937 |
| | Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity | Q24290192 |
| | A role for alpha-synuclein in the regulation of dopamine biosynthesis | Q24293727 |
| | Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation | Q24296620 |
| | Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 |
| | Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress | Q24320119 |
| | CRE recombinase-inducible RNA interference mediated by lentiviral vectors | Q24562287 |
| | Cre-lox-regulated conditional RNA interference from transgenes | Q24564248 |
| | Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1 | Q24647567 |
| | Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice | Q24673105 |
| | Current protocols in neuroscience | Q27721712 |
| | Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 |
| | RNA interference is mediated by 21- and 22-nucleotide RNAs | Q27860764 |
| | Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells | Q28115626 |
| | In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin | Q28144676 |
| | Killing the messenger: short RNAs that silence gene expression | Q28207880 |
| | Multiple sclerosis | Q28214785 |
| | In vitro activation of the transcription factor ISGF3 by interferon alpha involves a membrane-associated tyrosine phosphatase and tyrosine kinase | Q28267305 |
| | Alpha-synuclein in the nucleus accumbens induces changes in cocaine behaviour in rats | Q28569567 |
| | Silencing dopamine D3-receptors in the nucleus accumbens shell in vivo induces changes in cocaine-induced hyperlocomotion | Q28578960 |
| | SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis | Q28583941 |
| | Molecular control of spinal accessory motor neuron/axon development in the mouse spinal cord | Q28589611 |
| | Mistargeting hippocampal axons by expression of a truncated Eph receptor | Q28591071 |
| | The neural basis of drug craving: an incentive-sensitization theory of addiction | Q29547475 |
| | Risk alleles for multiple sclerosis identified by a genomewide study | Q29614890 |
| | A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference | Q29615920 |
| | Multiple sclerosis | Q29616022 |
| | AAA+ proteins: have engine, will work | Q29617410 |
| | Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo | Q30846112 |
| | Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors | Q31148881 |
| | Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes | Q31158487 |
| | Cocaine-induced expression of the tetraspanin CD81 and its relation to hypothalamic function | Q31937446 |
| | BACE1: the beta-secretase enzyme in Alzheimer's disease | Q33202614 |
| | Delay aversion but preference for large and rare rewards in two choice tasks: implications for the measurement of self-control parameters. | Q33247797 |
| | Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease? | Q33341237 |
| | Emerging restorative treatments for Parkinson's disease | Q33347369 |
| | Trinucleotide repeat length and progression of illness in Huntington's disease | Q33596210 |
| | Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation | Q33694463 |
| | Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease | Q33732191 |
| | Dopamine genes and ADHD. | Q33888395 |
| | SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. | Q33904273 |
| | Torsin A and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations | Q33907326 |
| | Triplet repeat expansion in neuromuscular disease | Q33936621 |
| | RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model | Q33936969 |
| | Association of the dopamine beta hydroxylase gene with attention deficit hyperactivity disorder: Genetic analysis of the Milwaukee longitudinal study | Q33965607 |
| | Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder | Q33977144 |
| | alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. | Q34076094 |
| | Genes and addiction | Q34076144 |
| | Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model | Q34105795 |
| | A polymorphic DNA marker genetically linked to Huntington's disease | Q34255139 |
| | Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders | Q34313088 |
| | TorsinA in the nuclear envelope | Q34336308 |
| | Recombinant proteins for neurodegenerative diseases: the delivery issue | Q34338244 |
| | Unlocking the potential of the human genome with RNA interference | Q34348958 |
| | Cocaine-induced expression changes of axon guidance molecules in the adult rat brain | Q34390929 |
| | The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein | Q34438326 |
| | Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin | Q34483577 |
| | Characterizing cognition in ADHD: beyond executive dysfunction | Q34491828 |
| | Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference | Q34520619 |
| | Is there a common genetic basis for autoimmune diseases? | Q34589958 |
| | The synuclein family | Q34663590 |
| | Animal models of Huntington's disease | Q34665829 |
| | IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. | Q34763506 |
| | Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi | Q34768688 |
| | The immunogenetics of multiple sclerosis | Q34776567 |
| | IL-21 signaling is critical for the development of type I diabetes in the NOD mouse | Q34823699 |
| | Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence. | Q35121761 |
| | Neuropathology of multiple sclerosis-new concepts. | Q35196334 |
| | Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. | Q35554495 |
| | Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord. | Q35618384 |
| | Experimental therapeutics in transgenic mouse models of Huntington's disease | Q35752429 |
| | RNA interference: from model organisms towards therapy for neural and neuromuscular disorders | Q35883332 |
| | Lentiviral vectors for use in the central nervous system. | Q36364923 |
| | Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. | Q36561684 |
| | Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease | Q36579852 |
| | Lentiviral vector mediated siRNA knock-down of hTERT results in diminished capacity in invasiveness and in vivo growth of human glioma cells in a telomere length-independent manner. | Q40111206 |
| | Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy | Q40151605 |
| | Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates | Q40159836 |
| | RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. | Q40203572 |
| | Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease | Q40230652 |
| | Silencing urokinase in the ventral tegmental area in vivo induces changes in cocaine-induced hyperlocomotion | Q40241285 |
| | BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome | Q40260424 |
| | siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells | Q40260791 |
| | Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi | Q40321534 |
| | Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. | Q40347828 |
| | Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter | Q40363580 |
| | Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model | Q40379114 |
| | Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. | Q40387759 |
| | Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells | Q40395753 |
| | Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease | Q40397185 |
| | Neuropsychological analyses of comorbidity between reading disability and attention deficit hyperactivity disorder: in search of the common deficit | Q40442012 |
| | In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. | Q40457375 |
| | Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease | Q40506120 |
| | Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors | Q40564517 |
| | Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector | Q40568114 |
| | Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. | Q40644113 |
| | Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. | Q40649450 |
| | Lentiviral vectors for gene delivery to normal and demyelinated white matter | Q40669514 |
| | The mechanism of gamma-secretase activities through high molecular weight complex formation of presenilins is conserved in Drosophila melanogaster and mammals | Q40696144 |
| | Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. | Q40723341 |
| | HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors | Q40738494 |
| | Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector | Q40741282 |
| | Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 |
| | Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. | Q40870371 |
| | Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease | Q40904090 |
| | Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation. | Q40932610 |
| | Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. | Q40983409 |
| | Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector | Q40997827 |
| | Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease | Q41151008 |
| | Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry | Q41614308 |
| | Lentivirus-delivered stable gene silencing by RNAi in primary cells | Q41996459 |
| | Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. | Q43206399 |
| | Regulation of EphB1 expression by dopamine signaling | Q43516635 |
| | Altered sensitivity of CD81-deficient mice to neurobehavioral effects of cocaine | Q43619890 |
| | Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model | Q43628011 |
| | Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum | Q43781780 |
| | Germline transmission of RNAi in mice | Q44283786 |
| | BACE1 Suppression by RNA Interference in Primary Cortical Neurons | Q44643912 |
| | Increased impulsive behavior and risk proneness following lentivirus-mediated dopamine transporter over-expression in rats' nucleus accumbens | Q44674396 |
| | Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice | Q44707365 |
| | Effective dephosphorylation of Src substrates by SHP-1. | Q44709195 |
| | Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. | Q44804036 |
| | CD81-induced behavioural changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus | Q44831654 |
| | Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice | Q44936994 |
| | RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. | Q44964949 |
| | Conditional gene expression and knockdown using lentivirus vectors encoding shRNA. | Q45164595 |
| | In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioural changes in chronic cocaine administration | Q45195004 |
| | Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains | Q45271574 |
| | Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. | Q45290978 |
| | Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment | Q45297544 |
| | Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 |
| | Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease | Q45304607 |
| | Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo | Q45306581 |
| | Natural history of multiple sclerosis in a population-based cohort | Q45767634 |
| | Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain | Q45870858 |
| | Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease | Q45877904 |
| | Gene therapy approaches for the treatment of Parkinson's disease | Q45880411 |
| | Cat and mouse | Q46184424 |
| | Executive functions in attention-deficit/hyperactivity disorder | Q36589259 |
| | Administration of the calcineurin inhibitor cyclosporine modulates cocaine-induced locomotor activity in rats | Q36952711 |
| | Preclinical development of gene therapy for Parkinson's disease | Q36955038 |
| | Huntington's disease: from pathology and genetics to potential therapies | Q37157909 |
| | Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD). | Q37260958 |
| | Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease | Q37713838 |
| | The role of protein tyrosine phosphatase SHP-1 in the regulation of IFN-gamma signaling in neural cells | Q38351176 |
| | Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice | Q39601884 |
| | Silencing of choline acetyltransferase expression by lentivirus-mediated RNA interference in cultured cells and in the adult rodent brain | Q39938073 |
| | RNA interference in silencing of genes of Alzheimer's disease in cellular and rat brain models. | Q39942419 |
| | The role of gamma-synuclein in cocaine-induced behaviour in rats | Q39966981 |
| | Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease | Q39995612 |
| | Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. | Q40038891 |
| | Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. | Q40047308 |
| | SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling | Q46218230 |
| | Effects of urokinase-type plasminogen activator in the acquisition, expression and reinstatement of cocaine-induced conditioned-place preference | Q46627257 |
| | Chromosome 5 and multiple sclerosis. | Q46649256 |
| | Targeting green fluorescent protein to dendritic membrane in central neurons. | Q46700936 |
| | The role of tissue-type plasminogen activator system in amphetamine-induced conditional place preference extinction and reinstatement | Q46767430 |
| | RNA inhibition of beta-secretase reverts AD in mice | Q46787462 |
| | Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. | Q46798860 |
| | RNAi blocks DYT1 mutant torsinA inclusions in neurons | Q46839227 |
| | Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation | Q48101693 |
| | Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. | Q48146867 |
| | Reinforcing effects of morphine are reduced in tissue plasminogen activator-knockout mice | Q48265424 |
| | Frontal, temporal and lateralized brain function in children with attention-deficit hyperactivity disorder: a psychophysiological and neuropsychological viewpoint on development | Q48409228 |
| | Attention deficit/hyperactivity disorder--from brain dysfunctions to behaviour | Q48409273 |
| | pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity | Q48463355 |
| | Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization | Q48576876 |
| | MeCP2-dependent transcriptional repression regulates excitatory neurotransmission | Q48596466 |
| | Lentiviral delivery of RNAi in hippocampal neurons | Q48653567 |
| | Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions | Q48777649 |
| | RNAi-induced down-regulation of Mecp2 expression in the rat brain. | Q50639417 |
| | Clinical features and psychiatric comorbidity of subjects with pathological gambling behavior. | Q51989522 |
| | Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. | Q52107054 |
| | Editorial | Q56764994 |
| | Dual-promoter lentiviral vectors for constitutive and regulated gene expression in neurons | Q60643618 |
| | Tolcapone: COMT inhibition for the treatment of Parkinson's disease | Q64891739 |
| | Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes | Q73396817 |
| | Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA | Q73470858 |
| | Classification of dystonia | Q77340778 |
| | Actions of neuropoietic cytokines and cyclic AMP in regenerative conditioning of rat primary sensory neurons | Q79368223 |
| | Lentiviral strategies for RNAi knockdown of neuronal genes | Q81131029 |
| | Editorial | Q94432882 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | RNA interference | Q201993 |
| | gene silencing | Q1431332 |
| | gene delivery | Q2790163 |
| P304 | page(s) | 169-187 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Molecular Biotechnology | Q15761195 |
| P1476 | title | Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions | |
| | Lentiviral Vector-Mediated Gene Transfer and RNA Silencing Technology in Neuronal Dysfunctions | |
| P478 | volume | 47 | |